Breast Cancer Blog

The Breast Cancer Blog at Cristine Meredith Miele Foundation contains frequent updates on the topics of breast cancer, cancer research, cancer treatment and risk assessment. It is where we put interesting new findings and help to keep you apprised of important new developments.
<< First  < Prev   1   2   Next >  Last >> 
  • 05 Sep 2014 1:01 PM | Anonymous
    This article has been republished from Surgical Products Magazine

    The breast cancer therapeutics pipeline boasts a high degree of innovation in first-in-class molecules, with many new technologies holding the potential to transform the clinical and commercial treatment landscape over the coming decade, says business intelligence provider GBI Research.

    The company’s latest report states that breast cancer has the largest drug pipeline in the pharmaceutical industry, with 816 products in active development across all stages. Of these treatments, GBI Research has identified 245 first-in-class programs acting on 175 first-in-class molecular targets, accounting for 39% of all products with a disclosed molecular target.

    Dominic Trewartha, Analyst for GBI Research, says: “The mechanisms of action in the breast cancer pipeline cover an extremely diverse range. Traditional chemotherapies and hormone therapies, for example, represent just 22% of the total pipeline, while there is an increasing move towards developing therapies that directly target proliferative signaling pathways. These therapies account for 31% of the pipeline.”

    According to GBI Research, the most widely studied, first-in-class targets in the breast cancer pipeline are signal transducer proteins. These are components of proliferative and survival-promoting signaling pathways, such as Ras/MAPK and PI3K/Akt, which operate downstream of the receptor. It is now understood that these agents share a high degree of crosstalk with one another.

    Trewartha continues: “Most first-in-class products in the breast cancer pipeline currently reside between the discovery and preclinical stages of development, although there are some in Phase I through to Phase III.

    “Despite the high failure rates witnessed in clinical trials, many first-in-class products will reach the market within the next decade, providing new therapies to currently underserved patient segments with significant unmet needs.”

    GBI Research also states that the challenge to develop products targeting novel rather than well-established pathways is offset by the real potential to discover highly effective drugs, which could alter the treatment market dynamics, increase competition and help drive further therapeutic innovation in breast cancer.
  • 07 Aug 2014 11:47 AM | Anonymous

    A recent study conducted at the University of Cambridge found mutations in a third gene (PALB2) may raise the risk of the breast cancer in women almost as much as mutations in BRCA1 and BRCA2. Published in the New England Journal of Medicine, the study found a woman with a PALB2 mutation has a 35 percent chance of developing cancer by age 70. 

    Click here to read the full article in the New York Times.

  • 23 May 2014 10:18 AM | Anonymous
    A recent article in the Wall Street Journal emphasizes the importance of mammograms for the detection of breast cancer. The article addresses the importance that women have access to affordable screenings. 

  • 01 Apr 2014 6:51 PM | Anonymous

    Our deepest thanks to Jennifer Kane and Fuel Fitness of Fair Haven, NJ.  In October, 2013, a number of classes were held at Fuel Fitness to benefit our Foundation. Through her efforts, Jennifer raised over $1,000 for CMMF.  We are deeply grateful. Thank you for keeping the memory and mission of Crissy alive!

    Click here for more information about Fuel Fitness of Fair Haven, NJ.

  • 22 Oct 2013 6:13 PM | Anonymous
    The Parker Family Health Center officially announces its partnership with the Cristine Meredith Miele Foundation to increase efforts in early detection and breast cancer prevention.

    Since 2010, CMMF has worked to raise money for cancer research projects in honor of Cristine Miele. The foundation is dedicated to continuing support for local efforts where it can, "make a direct impact on someone's life."

  • 15 May 2013 10:30 AM | Anonymous
    Angelina Jolie recently made headlines after making the brave choice to undergo a preventative double mastectomy. She watched her mother fight breast cancer for nearly a decade before succumbing to the disease; therefore, she decided to receive BRCA testing.

    When she learned she carried the "faulty BRCA1", she chose to be proactive against the disease to dramatically minimize her risk for both breast cancer and ovarian cancer. Read her full story from the New York Times.
  • 01 May 2013 12:53 PM | Anonymous

    Scientists are discovering more similarities among cancers originating in different bodily organs. Findings such as these further the idea that cancers and their subsequent treatments will be classified by a "genetic fingerprint" rather than their place of origin. Read the full New York Times article.

  • 25 Apr 2013 10:00 AM | Anonymous
    Cancer centers are investing a lot of money in the technology of human genome sequencing. These analyses could serve to further "precision medicine", by which the prevention and treatment of disease, cancer included, is based on a person's unique genetic makeup. This type of testing is still very expensive, and the drawback is mapping for diseases a person will never have; however, sequencing for some could mean knowing ahead of time which steps to take to prevent a serious diagnosis in the future. Read the full New York Times article here.
  • 16 Jan 2013 9:00 AM | Anonymous
    One man’s brave and selfless final act could impact cancer research world wide. When Dr. Ralph Steinman was diagnosed with pancreatic cancer in 2007, a disease which kills 80 percent of its victims within the first year of diagnosis, he used his scientific background to try everything to beat his cancer. Read the full New York Times article here.
  • 28 Dec 2012 10:00 AM | Anonymous

    Through new drug testing, scientists hope to use a certain protein to block the growth of multiple cancers, regardless of origin. The research centers around a protein called P53 that essentially tells a normal, healthy cell to die if its DNA is too badly damaged. Cancer cells block this protein, allowing for the replication of the damaged cells. Scientists are now aiming to find a drug that could release molecules into a pocket between the P53 protein and the blocking protein, MDM2, to prevent P53 from being disabled. 

    If this research proves successful, it could be welcome news for people with more rare types of cancer whose treatments have been neglected due to lack of knowledge of the cancer. Click here to read the full New York Times article. 

<< First  < Prev   1   2   Next >  Last >> 

© 2010 Cristine Meredith Miele Foundation, Inc. | All rights reserved | Privacy Policy | Terms & Conditions | Contact Us

Powered by Wild Apricot Membership Software